Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

NCT07709585 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

124

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer (NSCLC)
EGFR Exon 19 Deletion Mutation
EGFR Exon 21 Mutation
EGFR Exon 21 L858R Mutation

Interventions

DRUG: Befotinib
DRUG: Pemetrexed + Cisplatin /Carboplatin

Sponsor

Guangzhou University of Traditional Chinese Medicine

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]